
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Bologna, Italia e Morristown, New Jersey, Stati Uniti d’America – 26 settembre
Bologna, Italia e Morristown, New Jersey, Stati Uniti d’America – 26 settembre
CARE&GO is Alfasigma's innovative summer social campaign, which will accompany travelers during the summer period, giving advice easy to put into practice everyday.
Connecting the Dots was the main topic of the third Global Leadership
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.
You’re entering Alfasigma global website
I agree